LAUER REGAN J 4
4 · ImmunityBio, Inc. · Filed Feb 12, 2026
Research Summary
AI-generated summary of this filing
ImmunityBio (IBRX) Chief Accounting Officer Exercises RSUs, Sells Shares
What Happened
Regan J. Lauer, Chief Accounting Officer of ImmunityBio (IBRX), had 5,482 restricted stock units (RSUs) vest on February 10, 2026. Those RSUs converted into 5,482 shares (reported as an exercise/conversion of a derivative). To cover tax withholding, 2,257 of those shares were withheld/sold at $6.93 per share, generating proceeds of $15,641. Net shares delivered to Lauer after withholding were 3,225 shares.
Key Details
- Transaction date: February 10, 2026 (Form 4 filed February 12, 2026 — timely filing).
- RSU conversion: 5,482 shares issued at $0.00 (conversion of RSUs).
- Tax withholding/sale: 2,257 shares disposed at $6.93 for $15,641 (transaction code F).
- Net shares received: 5,482 − 2,257 = 3,225 shares retained by insider.
- Footnotes: F1–F3 confirm RSUs convert 1:1 into common stock and that the Feb 9, 2026 closing price was used to calculate shares withheld; the award vests per a 3‑year schedule (vesting commencement Feb 10, 2025).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Nature: This is an RSU vesting event with routine tax withholding (not an open‑market purchase or discretionary sale).
Context
RSU vesting is a common form of compensation conversion into stock; withholding/sale of shares to cover taxes is routine and does not necessarily signal a change in the insider’s view of the company. The filing shows conversion of the derivative award and the associated tax withholding rather than a voluntary market sale or new purchase.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-10+5,482→ 115,740 total - Tax Payment
Common Stock
[F2]2026-02-10$6.93/sh−2,257$15,641→ 113,483 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-02-10−5,482→ 10,965 total→ Common Stock (5,482 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
- [F2]On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld.
- [F3]Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.